m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00618)
Name
Bis(5-hydroxybenzo[b]furan-2-yl)methanone
Synonyms
CHEMBL225826; bis(5-hydroxybenzo[b]furan-2-yl)methanone
    Click to Show/Hide
Status
Investigative
Structure
Formula
C17H10O5
InChI
1S/C17H10O5/c18-11-1-3-13-9(5-11)7-15(21-13)17(20)16-8-10-6-12(19)2-4-14(10)22-16/h1-8,18-19H
InChIKey
TYHFGEDRLCAJMH-UHFFFAOYSA-N
PubChem CID
13454380
TTD Drug ID
D02OBA
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Platelet-derived growth factor receptor beta (PDGFRB)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Platelet-derived growth factor receptor beta (PDGFRB) is a therapeutic target for Bis(5-hydroxybenzo[b]furan-2-yl)methanone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Bis(5-hydroxybenzo[b]furan-2-yl)methanone through regulating the expression of Platelet-derived growth factor receptor beta (PDGFRB). [1], [2]
References
Ref 1 Mutant NPM1-Regulated FTO-Mediated m(6)A Demethylation Promotes Leukemic Cell Survival via PDGFRB/ERK Signaling Axis. Front Oncol. 2022 Feb 8;12:817584. doi: 10.3389/fonc.2022.817584. eCollection 2022.
Ref 2 Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays. Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8. doi: 10.1016/j.bmcl.2006.11.006. Epub 2006 Nov 7.